ASTHMA ALLERGY AND INFLAMMATION RESEARCH TRUST LIMITED

Registered charity 1129698 · accounts filings on the Charity Commission register · also known as AAIR, ASTHMA & ALLERGY RESEARCH

Latest income
£320k
Latest spending
£90k
Registered
2009
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that the charity achieved an overall surplus of £258,012 for the year ended 31 August 2025, driven primarily by legacies totaling £305,151. Unrestricted funds increased to £623,712, which significantly exceeds the charity's stated reserves policy target of retaining at least £100,000. The trustees confirm that resources are adequate to continue operations with no material uncertainties identified.

What the accounts disclose

Reserves policy: at least £100,000 of Uncommitted Funds (held: £624k)
the charity's policy is to retain at least £100,000 of Uncommitted Funds, this level being reviewed annually.
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Administrative services paid to a company where trustee Mr L A Dunn has an interest.
During the year, £13,976 (2024: £12,778) was payable to a company in which the trustee, Mr L A Dunn, has an interest, for administrative services provided to the charity by two of that company's employees. No benefit accrues to Mr Dunn, or the company in which he has an interest, the additional costs to the company (including salary and Employers' National Insurance) being matched by payments made by the charity. At 31 August 2025, £Nil (2024: £Nil) was unpaid and £Nil (2024: £1,660) was accrued in respect of the services provided during the year. — page 28
During the year, no grants were awarded for research projects in which trustees had an interest (2024: One grant totalling £10,000). — page 28
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Research grants awarded to trustees' projects.
During the year, £13,976 (2024: £12,778) was payable to a company in which the trustee, Mr L A Dunn, has an interest, for administrative services provided to the charity by two of that company's employees. No benefit accrues to Mr Dunn, or the company in which he has an interest, the additional costs to the company (including salary and Employers' National Insurance) being matched by payments made by the charity. At 31 August 2025, £Nil (2024: £Nil) was unpaid and £Nil (2024: £1,660) was accrued in respect of the services provided during the year. — page 28
During the year, no grants were awarded for research projects in which trustees had an interest (2024: One grant totalling £10,000). — page 28
Per its FY2025 accounts as filed with the Charity Commission.

Accounts independently examined (not a full audit).

Corporate structure

Public fundraising profile: JustGiving — AAIR Charity (Asthma, Allergy & inflammation Research) (matched by registered charity number).

Trustees

Trustee list from the Charity Commission register (current, not historical).

Operates in: Throughout England And Wales

Income and spending

Financial year endIncomeSpending
31/08/2025£320k£90k
31/08/2024£48k£97k
31/08/2023£47k£80k
31/08/2022£8k£68k
31/08/2021£36k£141k

Common questions

Is ASTHMA ALLERGY AND INFLAMMATION RESEARCH TRUST LIMITED financially healthy?

The accounts state that the charity achieved an overall surplus of £258,012 for the year ended 31 August 2025, driven primarily by legacies totaling £305,151. Unrestricted funds increased to £623,712, which significantly exceeds the charity's stated reserves policy target of retaining at least £100,000. The trustees confirm that resources are adequate to continue operations with no material uncertainties identified. Its FY2025 accounts were independently examined.

Funders of similar charities

Funders whose accounts show grants to charities similar to this one (and no recorded grant to this charity) — a starting list for fundraisers.

Charities like this

Semantically similar by activities and financial character, from our analysed corpus. Compare with BOURNEMOUTH AND POOLE HEALTHCARE TRUST (1).